GlobeNewswire·May 4, 2026, 7:30 AM ET

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

MacroGenics, Inc. entered an expanded royalty purchase agreement with Sagard regarding ZYNYZ (retifanlimab-dlwr) on May 4, 2026.
This agreement follows an initial ZYNYZ royalty purchase agreement signed by both parties in June 2025.
MacroGenics received a $60 million upfront payment from Sagard under the terms of the new deal.
MacroGenics is eligible for an additional sales-based milestone of up to $20 million for 2026 sales.
Royalty rights revert to MacroGenics once Sagard recovers either 1.7x its investment by September 30, 2032, or 2.0x its investment at any time thereafter.
ZYNYZ is a PD-1 inhibitor licensed to Incyte Corporation in October 2017, which markets the drug in the U.S.
ZYNYZ is indicated for squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy in the U.S., Europe, and Japan, as a single agent for SCAC progression in the U.S., and as monotherapy for Merkel cell carcinoma in the U.S., EU, Canada, and Switzerland.
MacroGenics retains economic interests including future development, regulatory, and commercial milestones for ZYNYZ.
Details of the agreement were filed in a Current Report on Form 8-K with the U.S. Securities and Exchange Commission.